Homocysteine Serum Levels and Methylenetetrahydrofolate (MTHFR) C677T Genotype in Patients with Parkinson's Disease, with and without Levodopa Therapy _ Crimson Publishers
Homocysteine Serum Levels and Methylenetetrahydrofolate (MTHFR) C677T Genotype in Patients with Parkinson's Disease, with and without Levodopa Therapy by Eleonora DŽoljić* and Vladimir Kostić in Degenerative Intellectual & Developmental Disabilities
Both methylenetetrahydrofolate (MTHFR) C677T genotype and levodopa
treatment may give rise to elevated serum homocysteine levels in
parkinsonian patients. We aimed to clarify the interplay of these
factors in pathogenesis of Parkinson's disease (PD)-related
hyperhomocysteinemia. Total serum levels of homocysteine (tHcy) and
MTHFR C677T genotype were investigated in levodopa-treated and
-untreated parkinsonian ("de novo”) patients, as well as in control
healthy subjects matched by age and gender (N=83, 30 and 53,
respectively). MTHFR C677T genotypes were equally distributed in PD patients and control subjects, the T allele homozygosity being observed
in app. 12-17% cases.
For more open access journals in Crimson Publishers please click on link: https://crimsonpublishers.com/
For more articles in open access Disabilities journals please click on link: https://crimsonpublishers.com/didd/
Comments
Post a Comment